Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
CNY 19.75
(-1.55%)
CNY 19.75
(-1.55%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -358.25 Million CNY | 79.13% |
| 2022 | -1.71 Billion CNY | -821.15% |
| 2021 | 238.03 Million CNY | 193.3% |
| 2020 | -255.13 Million CNY | -966.23% |
| 2019 | -23.92 Million CNY | -7.16% |
| 2018 | -22.33 Million CNY | 54.52% |
| 2017 | -49.09 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 337.85 Million CNY | 92.83% |
| 2024 Q1 | 175.2 Million CNY | 148.91% |
| 2024 Q3 | 470.6 Million CNY | 40.99% |
| 2023 Q4 | -358.25 Million CNY | 40.94% |
| 2023 Q3 | -606.58 Million CNY | 34.55% |
| 2023 FY | -358.25 Million CNY | 79.13% |
| 2023 Q2 | -926.79 Million CNY | 27.8% |
| 2023 Q1 | -1.28 Billion CNY | 25.22% |
| 2022 Q3 | -2.09 Billion CNY | 17.1% |
| 2022 Q4 | -1.71 Billion CNY | 18.04% |
| 2022 FY | -1.71 Billion CNY | -821.15% |
| 2022 Q2 | -2.52 Billion CNY | 5.45% |
| 2022 Q1 | -2.67 Billion CNY | -1222.49% |
| 2021 Q4 | 238.03 Million CNY | 2488.51% |
| 2021 Q2 | 65.86 Million CNY | -87.98% |
| 2021 Q1 | 547.91 Million CNY | 314.76% |
| 2021 FY | 238.03 Million CNY | 193.3% |
| 2021 Q3 | -9.96 Million CNY | -115.13% |
| 2020 Q4 | -255.13 Million CNY | 0.0% |
| 2020 FY | -255.13 Million CNY | -966.23% |
| 2020 Q2 | -75.85 Million CNY | 0.0% |
| 2019 FY | -23.92 Million CNY | -7.16% |
| 2018 FY | -22.33 Million CNY | 54.52% |
| 2017 FY | -49.09 Million CNY | 0.0% |